Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22
March 28, 2022 at 10:19 AM EDT
Iterum Therapeutics plc(NASDAQ: ITRM) has incurred aQ4 FY21 EPS loss of $(0.02)versus $(0.28) reported a year ago and ...